MARKET

INO

INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.190
-0.085
-1.99%
After Hours: 4.190 0 0.00% 19:58 01/19 EST
OPEN
4.270
PREV CLOSE
4.275
HIGH
4.370
LOW
4.170
VOLUME
3.57M
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
4.170
MARKET CAP
881.52M
P/E (TTM)
-3.8571
1D
5D
1M
3M
1Y
5Y
Hot Stocks: Meme stocks fall; MSFT buys ATVI; SI drops on earnings; HMHC looking to sell; UL looking to buy
Stock traders returned after the three-day holiday weekend with selling on their minds. The major averages posted notable losses, led by a 2.6% drop in the Nasdaq. Amid the selling
Seekingalpha · 1d ago
AMC, GameStop lead meme stocks lower despite new squeeze effort
The term "#AMCSqueeze" is again trending on Twitter, showing conversation has sparked back up around going long on meme stocks despite a rout in nearly all names (outside videogames). AMC
Seekingalpha · 1d ago
Bill Gates Says Misinformation Related To Fauci, Himself Doesn't 'Make Sense,' Talks COVID-19 After Omicron
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates answered questions related to COVID-19 on Twitter Tuesday.
Benzinga · 01/12 04:15
Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the sto...
Zacks · 01/11 15:00
Inovio assumed with Hold at Jefferies with $6 target
Jefferies analyst Roger Song assumed coverage of Inovio Pharmaceuticals (INO -2.4%) with a Hold rating and price target (PT) of $6, down from $8. The analyst believes near-term stock movement
Seekingalpha · 12/29/2021 14:55
If You Invested $1,000 In Inovio Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 29.2%. But there is no question some big-name stocks performed better than others alon...
Benzinga · 12/27/2021 19:11
Is Israel's fourth COVID vaccine dose a sign of things to come?
Israel is set to become the first country in the world to administer a fourth COVID-19 vaccine, which would give "greater protection in the face of Omicron." The first eligible
Seekingalpha · 12/22/2021 10:44
Is Inovio Stock A Buy After The FDA Removed Its Hold On Covid Vaccine Testing?
Is INO stock a buy after the Food and Drug Administration removed a hold barring the Inovio from testing its Covid vaccine in the U.S.?
Investor's Business Daily · 12/21/2021 22:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.11%Strong Buy
22.22%Buy
55.56%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average INO stock price target is 13.63 with a high estimate of 35.00 and a low estimate of 6.00.
High35.00
Average13.63
Low6.00
Current 4.190
EPS
Actual
Estimate
-0.31-0.23-0.16-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 334
Institutional Holdings: 80.04M
% Owned: 38.04%
Shares Outstanding: 210.39M
TypeInstitutionsShares
Increased
58
6.98M
New
32
694.00K
Decreased
59
3.27M
Sold Out
23
749.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.06%
Pharmaceuticals & Medical Research
-0.76%
Key Executives
Non-Executive Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Non-Executive Vice Chairman/Independent Director
Jay Shepard
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Human Resource Officer
Asli Gevgilili
Chief Scientific Officer
Laurent Humeau
General Counsel
Robert Crotty
Other
Gene Kim
Other
Mark Twyman
Director
Roger Dansey
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
No Data
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.